MusclePharm market cap is $38.2 m, and annual revenue was $64.44 m in FY 2020

MusclePharm Gross profit (FY, 2020)19.6 M

MusclePharm Gross profit margin (FY, 2020), %30.4%

MusclePharm Net income (FY, 2020)3.2 M

MusclePharm EBIT (FY, 2020)2.6 M

MusclePharm Cash, 31-Dec-20202 M

MusclePharm EV52.7 M

MusclePharm revenue was $64.44 m in FY, 2020

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 17.2m | 67.1m | 110.9m | 177.4m | 166.9m | 132.5m | 102.2m | 79.7m | 64.4m |

| (6%) | (21%) | |||||||

## Cost of goods sold | 14.8m | 52.7m | 77.7m | 121.4m | 109.9m | 88.0m | 71.7m | 71.0m | 44.8m |

## Gross profit | 2.4m | 14.3m | 33.2m | 56.0m | 56.9m | 44.5m | 30.4m | 8.7m | 19.6m |

| 14% | 21% | 30% | 32% | 34% | 34% | 30% | 11% | 30% |

## Sales and marketing expense | 8.4m | 15.5m | 28.1m | 27.0m | 10.7m | 9.4m | 2.5m | 507.0k | |

## R&D expense | 1.1m | 4.0m | 4.3m | 1.9m | 642.0k | 893.0k | |||

## General and administrative expense | 18.6m | 23.1m | 47.5m | 13.4m | 19.4m | 15.9m | 12.1m | 8.9m | 7.1m |

## Operating expense total | 18.6m | 23.1m | 47.5m | 75.4m | 106.9m | 53.1m | 37.6m | 23.8m | 17.0m |

## EBIT | (16.2m) | (8.7m) | (14.3m) | (19.4m) | (49.9m) | (8.7m) | (7.2m) | (15.1m) | 2.6m |

| (94%) | (13%) | (13%) | (11%) | (30%) | (7%) | (7%) | (19%) | 4% |

## Interest expense | 3.7m | 7.3m | 783.3k | 5.6m | |||||

## Interest income | 250.0k | 50.0k | 1.4m | ||||||

## Pre tax profit | (17.6m) | (13.8m) | (51.8m) | (3.2m) | (10.8m) | (18.8m) | 3.2m | ||

## Income tax expense | 115.5k | 33.0k | 105.0k | 318.0k | (108.0k) | 86.0k | (19.0k) | ||

## Net Income | (23.3m) | (19.0m) | (17.7m) | (13.8m) | (51.9m) | (3.5m) | (11.0m) | (18.9m) | 3.2m |

USD | Q2, 2011 |
---|---|

## Debt/Equity | -0.4 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | -0.9 x |